13F HOLDINGS REPORT
Decheng Capital LLC
Quarter ended Q2 2024 · Filed August 14, 2024 · Accession 0001104659-24-089453
Total Value
$326.3M
Positions
24
Other Managers
0
Confidential Omitted
No
Holdings (24)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CG ONCOLOGY INC | CGON | 5,458,810 | $172.3M | 52.81% |
| 2 | Nuvation Bio Inc. | NUVB | 6,950,239 | $20.3M | 6.22% |
| 3 | Arcus Biosciences, Inc | RCUS | 869,790 | $13.2M | 4.06% |
| 4 | Zentalis Pharmaceuticals Inc. | ZNTL | 3,070,442 | $12.6M | 3.85% |
| 5 | KRYSTAL BIOTECH INC | KRYS | 65,772 | $12.1M | 3.70% |
| 6 | BeyondSpring Inc. | BYSI | 4,958,143 | $11.9M | 3.65% |
| 7 | Illumnia, Inc. | ILMN | 108,767 | $11.4M | 3.48% |
| 8 | MERUS NV | N5749R100 | 179,098 | $10.6M | 3.25% |
| 9 | PHATHOM PHARMACEUTICALS INC | PHAT | 850,000 | $8.8M | 2.68% |
| 10 | NEWAMSTERDAM PHARMA CO NV | NAMSW | 400,000 | $7.7M | 2.35% |
| 11 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 166,600 | $7.3M | 2.24% |
| 12 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 347,835 | $7.3M | 2.24% |
| 13 | CRINETICS PHARMACEUTICALS IN | CRNX | 157,958 | $7.1M | 2.17% |
| 14 | CYTOKINETICS INC | CYTK | 94,043 | $5.1M | 1.56% |
| 15 | LEGEND BIOTECH CORP-ADR | LEGN | 98,558 | $4.4M | 1.34% |
| 16 | Aura Biosciences, Inc. | AURA | 515,555 | $3.9M | 1.19% |
| 17 | Equillium Inc. | EQ | 4,447,308 | $3.1M | 0.94% |
| 18 | GeneDx Holdings Corp. | WGSWW | 103,604 | $2.7M | 0.83% |
| 19 | VERA THERAPEUTICS INC | VERA | 69,767 | $2.5M | 0.77% |
| 20 | Pyxis Oncology, Inc (formerly Apexigen) | PYXS | 326,810 | $1.1M | 0.33% |
| 21 | AtriCure Inc. | ATRC | 26,797 | $610,168 | 0.19% |
| 22 | GRAIL INC | GRAL | 18,127 | $278,612 | 0.09% |
| 23 | Nuvation Bio Inc. | NUVB | 646,057 | $103,369 | 0.03% |
| 24 | ARCELLX INC | ACLX | 1,177 | $64,959 | 0.02% |